Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
Notice of Extraordinary General Meeting in Phase Holographic Imaging PHI AB (publ)
Notice to the shareholders in Phase Holographic Imaging AB (publ), 556542-7811, to attend an Extraordinary General Meeting on Monday June 18 at 06.00 PM (18.00) at PHI’s office, Scheelevägen 22, Lund.
Decision on rights issue for continued growth, establishment of sales organization and commercial break-through
The Board of directors of Phase Holographic Imaging PHI AB (publ) (”PHI”) has decided to conduct a rights issue of units, which is subject to approval on Extraordinary General Meeting, that can provide the company a total of SEK 64.6 million at the most prior to issuing costs.
HoloMonitor M4 at Pazmany Peter Catholic University
Dr Garay Tamás’ research focuses on cell migration and proliferation in cancer cells. HoloMonitor M4, with it’s potential to track cell events in a cell friendly environment inside the incubator will, hopefully, be a helpful tool for Dr Garay Tamas in his future research.
PHI increase sales in fourth quarter, as well
PHI hereby announces that net sales during the fourth and final fiscal quarter of 2017/18 amounted to 2.2 (1.2) MSEK, resulting in that the company saleswise achieves its best quarter ever for the second consecutive quarter.
PHI and world-leading research institute evaluate quantitative imaging of living tumor cells
QIMR Berghofer Medical Research Institute in Brisbane and PHI have entered an evaluation agreement to explore the use of live cell time-lapse cytometry based on quantitative phase microscopy to determine the impact of hypoxic microenvironment on cellular motility and metastatic potential in solid cancers.
AACR 2018
Phase Holographic Imaging | AACR 2018 Be among the first to see a walk-through of the HoloMonitor App Suite – a new proprietary software for analysis of images and data, especially developed for cell biological applications. Meet us for a demo – visit our booth #1740.
Phase Holographic Imaging launches new website
Today Phase Holographic Imaging (PHI) launches a new website. The new website has been created to comprehensively provide extensive product information, as well as an introduction to the range of cell biology applications supported by the HoloMonitor® system.
University of California, San Francisco and Phase Holographic Imaging establish Center of Excellence
University of California, San Francisco (UCSF) and Phase Holographic Imaging (PHI) have agreed to expand their on-going collaboration and establish a regional Holographic Imaging Cytometry Center of Excellence, located at the UCSF Helen Diller Family Comprehensive Cancer Center.
Novel HoloMonitor method identifies tumor creating cancer cells
Using HoloMonitor®, researchers at Harvard Medical School and Boston Children’s Hospital have developed a novel non-invasive method for distinguishing between active and dormant cancer cells.
New CEO commentary: “The scientific role of commercialization”
On PHI’s website, founder and CEO Peter Egelberg comments on his presentation at SPIE 2018 in San Francisco “The evolution of Phase Holographic Imaging from a research idea to publicly traded company”, see CEO commentary The scientific role of commercialization, published February 18, 2018.